title: Medical treatment of benign prostatic hyperplasia.
abstract: Medical therapy for the treatment of benign prostatic hyperplasia (BPH) became an accepted standard of care in the 1990s following the reports of randomized, double-blind, placebo-controlled studies showing that finasteride, a 5-α reductase inhibitor, and terazosin, an α-blocker, significantly improved lower urinary tract symptoms and increased peak urinary flow rates in men with BPH. This article reviews novel approaches to the pharmacological treatment of BPH.
authors.affiliation: New York University School of Medicine New York, NY.
authors.forename: Herbert
authors.initials: H
authors.lastname: Lepor